Latest Period
Q2 2026
Security Snapshot
HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share (HRTX) Institutional Ownership
CUSIP: 427746102
13F Institutional Holders and Ownership History from Q1 2014 to Q2 2026
Institutions Reporting
160
Shares (Excl. Options)
133,376,926
Price
$0.43
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.01 per share
- Symbol
- HRTX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 133,376,926
- Total 13F value
- $56,992,908
- Portfolio coverage rank
- 0%
- Share change
- -23,160,139
- Value change
- -$17,194,019
- Number of holders
- 160
- Shares outstanding
- 182,615,507
- SEC-reported price per share
- $0.34
- Insider filing price
- $0.34
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- HRTX - HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share is tracked under CUSIP 427746102.
- 160 institutions reported positions in Q2 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 163 to 160 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $125,311,516 to $56,992,908.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 160 institutions filings for Q2 2026.
Security key
427746102
Latest holder period
Q2 2026
13F holders
160
13D/G owners
2
CIK / CUSIP context first
Open Q2 2026 holders
HRTX full holder history
HERON THERAPEUTICS, INC. /DE/ SEC filings
HERON THERAPEUTICS, INC. /DE/ company facts
HERON THERAPEUTICS, INC. /DE/ insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 427746102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
HRTX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Rubric Capital Management LP | 16% | -8.9% | $37,859,003 | +$1,192,086 | 30,046,828 | +3.3% | Rubric Capital Management LP | 15 Oct 2025 |
| Clearline Capital LP | 6.7% | +28% | $18,108,154 | +$3,733,614 | 12,235,239 | +26% | Clearline Capital LP | 31 Dec 2025 |
As of 30 Jun 2026, 160 institutional investors reported holding 133,376,926 shares of HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share (HRTX). This represents 73% of the company’s total 182,615,507 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
66%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Rubric Capital Management LP | 16% | 30,046,828 | 0% | 0.12% | $12,823,986 |
| Clearline Capital LP | 6.2% | 11,383,961 | -7% | 0.31% | $4,858,675 |
| BlackRock, Inc. | 5.8% | 10,550,750 | +4.4% | 0% | $4,503,060 |
| Velan Capital Investment Management LP | 4.8% | 8,753,290 | 0% | 2.3% | $3,735,904 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.3% | 7,782,741 | -0.35% | 0% | $3,323,230 |
| Tejara Capital Ltd | 3.6% | 6,510,795 | +2.7% | 1.1% | $2,778,807 |
| TANG CAPITAL MANAGEMENT LLC | 3.4% | 6,250,000 | 0% | 0.12% | $2,667,500 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.3% | 4,270,980 | +6.5% | 0% | $1,823,405 |
| MILLENNIUM MANAGEMENT LLC | 2.2% | 4,070,101 | -47% | 0% | $1,737,119 |
| JW Asset Management, LLC | 2.1% | 3,751,073 | 0% | 0.5% | $1,600,958 |
| STATE STREET CORP | 1.8% | 3,228,557 | -16% | 0% | $1,377,948 |
| UBS Group AG | 1.6% | 2,997,073 | +31% | 0% | $1,279,750 |
| Pale Fire Capital SE | 1.4% | 2,511,478 | -7.5% | 0.08% | $1,071,899 |
| MARSHALL WACE, LLP | 1.3% | 2,354,193 | 0% | $1,012,302 | |
| Congress Park Capital LLC | 1.1% | 2,016,447 | -50% | 0.23% | $860,620 |
| Richmond Brothers, Inc. | 0.98% | 1,792,319 | +25% | 0.4% | $764,961 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.87% | 1,580,510 | +21% | 0% | $674,878 |
| AQR CAPITAL MANAGEMENT LLC | 0.85% | 1,553,857 | +142% | 0% | $663,186 |
| RENAISSANCE TECHNOLOGIES LLC | 0.83% | 1,506,900 | -12% | 0% | $643,145 |
| VANGUARD FIDUCIARY TRUST CO | 0.75% | 1,365,119 | +18% | 0% | $582,906 |
| GOLDMAN SACHS GROUP INC | 0.73% | 1,329,754 | +26% | 0% | $567,539 |
| PANAGORA ASSET MANAGEMENT INC | 0.7% | 1,281,796 | +33% | 0% | $547,071 |
| NORTHERN TRUST CORP | 0.67% | 1,223,480 | +4.3% | 0% | $522,181 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.67% | 1,217,463 | -12% | 0% | $519,613 |
| GSA CAPITAL PARTNERS LLP | 0.57% | 1,042,892 | +893% | 0.03% | $445,000 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
50
Latest
Q2 2026
Rows shown
1-25 of 50
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 133,376,926 | $56,992,908 | -$17,194,019 | $0.43 | 160 |
| 2026 Q1 | 156,622,767 | $125,311,516 | -$7,261,417 | $0.80 | 163 |
| 2025 Q4 | 156,364,163 | $203,259,393 | +$5,474,582 | $1.30 | 170 |
| 2025 Q3 | 152,658,767 | $192,362,843 | +$22,498,799 | $1.26 | 171 |
| 2025 Q2 | 131,463,843 | $272,131,676 | +$12,999,478 | $2.07 | 170 |
| 2025 Q1 | 124,770,231 | $274,489,898 | +$21,979,195 | $2.20 | 164 |
| 2024 Q4 | 114,941,581 | $175,829,179 | -$13,146,397 | $1.53 | 161 |
| 2024 Q3 | 121,816,811 | $242,421,216 | -$29,164,536 | $1.99 | 169 |
| 2024 Q2 | 129,609,461 | $453,638,008 | +$35,415,047 | $3.50 | 189 |
| 2024 Q1 | 119,262,673 | $330,361,469 | +$19,698,437 | $2.77 | 157 |
| 2023 Q4 | 112,451,511 | $191,165,565 | +$1,074,277 | $1.70 | 149 |
| 2023 Q3 | 118,378,841 | $121,934,068 | +$19,982,956 | $1.03 | 138 |
| 2023 Q2 | 98,652,577 | $114,435,495 | -$11,706,623 | $1.16 | 143 |
| 2023 Q1 | 107,852,430 | $162,855,915 | -$15,688,602 | $1.51 | 153 |
| 2022 Q4 | 115,831,665 | $289,582,111 | -$29,877,564 | $2.50 | 175 |
| 2022 Q3 | 121,963,764 | $514,346,608 | +$45,998,596 | $4.22 | 178 |
| 2022 Q2 | 115,204,514 | $321,404,107 | +$4,826,591 | $2.79 | 160 |
| 2022 Q1 | 108,535,070 | $620,478,626 | -$95,435,236 | $5.72 | 176 |
| 2021 Q4 | 117,646,567 | $1,073,655,355 | +$78,398,633 | $9.13 | 192 |
| 2021 Q3 | 108,488,554 | $1,160,926,758 | +$41,634,303 | $10.69 | 189 |
| 2021 Q2 | 103,864,409 | $1,612,145,175 | +$202,378,763 | $15.52 | 182 |
| 2021 Q1 | 89,846,972 | $1,456,395,898 | -$11,223,795 | $16.21 | 186 |
| 2020 Q4 | 90,262,699 | $1,910,380,366 | +$26,526,144 | $21.16 | 180 |
| 2020 Q3 | 90,857,946 | $1,346,585,988 | +$33,105,054 | $14.82 | 177 |
| 2020 Q2 | 88,614,685 | $1,334,393,703 | -$51,210,796 | $14.71 | 185 |